Kura Oncology is positioning ziftomenib (KOMZIFTI) as a combination backbone in AML, not just a relapsed/refractory ...
Vor Biopharma pivots to telitacicept for autoimmune diseases, backed by $491M cash to 2029. Click here to read an analysis of ...
ASCO 2026 highlighted a shift toward precision-driven oncology R&D, where biomarkers, ctDNA, and integrated strategies guide ...
Hengrui and Kailera have been vocal about positioning the drug as being capable of improving the clinical profile of existing ...
Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented ...
VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -- ...
Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has ...
Rituximab is poised for growth due to its established use in oncology and autoimmune diseases, strong commercial history, and proven efficacy. Despite biosimilar competition, its broad indications and ...
Merck’s MRK stock is trading above its 50-day and 200-day simple moving averages (SMAs), a positive technical signal that ...
AstraZeneca (LSE:AZN) secured European Union approval for Enhertu as the first HER2-directed antibody drug conjugate with a ...
Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results